Bristol-Myers Squibb Plans Significant Cost Cuts Amid Strategic Changes
SOURCENews reportView the filing ↗
What we know
Based on news reporting.
Summary
Bristol-Myers Squibb Company (BMS) has announced plans to enhance its cost-cutting measures by adding $2 billion to its existing budget. This decision comes in the wake of the successful launch of its new drug, Cobenfy, and reflects the company's strategic shift towards optimizing operations and exploring potential deals. While specific details regarding employee layoffs were not disclosed, the company is expected to implement significant workforce adjustments as part of its restructuring efforts. The exact timeline and number of positions affected remain unclear, but the move indicates a proactive approach to streamline operations in a competitive market.
LayoffTalk has tracked 30 layoff events at Bristol-Myers Squibb Company since November 2022, including 4,575 jobs documented in official WARN filings, with 17 additional events known from news reporting.
Comments (0)
Anonymous by default. Be kind — people reading this may be going through it right now.
No comments yet. Be the first to share your thoughts.
Estimated figure based on news reporting. Not yet confirmed by Bristol-Myers Squibb Company.
Affected by this?
Share your story anonymously — it helps others reading this feel less alone.
Share your story →More layoffs at Bristol-Myers Squibb Company
Recent tracked events at this company.